The Clinical Value of Oxymatrine in Preventing Lamivudine Induced YMDD Mutation: A Meta-Analysis

Table 1

Characteristics of the trials included in the meta-analysis.

References	Sample size (treatment/control)	Gender (male/female)	Age	Treatment duration (weeks)	YMDD mutation (pretreatment) (treatment/control)
Chen and Yang (2010) [20]	70/70	82/58	19∼61	52	0/0
Ding and Hua (2010) [21]	30/34^a	41/23	18∼49	260	0/0
Guo (2007) [22]	36/34	60/10	38.5	52	0/0
Guo et al. (2005) [23]	132/64	—/—	—	52	0/0
Hu and Zhao (2009) [24]	20/20	27/13	31.25	52	0/0
Huang (2007) [25]	33/34	52/15	19∼55	56	0/0
Huang et al. (2006) [26]	87/70	95/62	39.1	52	0/0
Li and Liang (2007) [27]	34/41	54/21	18∼58	52	0/0
Shen et al. (2005) [28]	62/57	—/—	18∼58	104	0/0
Sheng et al. (2006) [29]		109/26	18∼65	52∼104	0/0
Su (2005) [30]	30/30	—/—	34.89 ± 11.13	52	0/0
Wang (2008) [31]	64/64	77/51	18∼54	52	0/0
Wang (2009) [32]	31/34	38/27	50.1	48	0/0
Wu et al. (2009) [33]	50/50	54/46	22∼62	48	0/0
Zhao et al. (2010) [34]	40/43	52/31	16∼62	78	0/0
Zhou (2009) [35]	35/35	55/15	19∼61	52	0/0

Patients did not complete detection of YMDD mutation and data is shown.